Roche Won’t Change Avastin Price in UK, Despite NICE Cost-Effectiveness Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche, Bayer, Pfizer and Wyeth weigh their responses to NICE’s statement that their products to treat advanced and/or metastatic kidney cancer are not cost effective.
You may also be interested in...
Drug Price Versus Value: British Pharma Plans Public Debate In November
Having called for a public debate on how the United Kingdom values and provides access to new medicines, the Association of the British Pharmaceutical Industry is organizing to make it happen
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.